BICYCLIC PLASMA KALLIKREIN INHIBITORS

(19)

(11)

EP 3 033 332 B8

(12)	CORRECTED EUROPEAN PATENT SPECIFICATION
	Note: Bibliography reflects the latest situation

(15)	Correction information:
	Corrected version no 1 (W1 B1)

(48)	Corrigendum issued on:
	31.10.2018 Bulletin 2018/44

(45)	Mention of the grant of the patent:
	19.09.2018 Bulletin 2018/38

(21)	Application number: 14753140.4

(22)	Date of filing: 14.08.2014

(51)

International Patent Classification (IPC):

C07D 401/04^(2006.01)
A61P 27/00^(2006.01)

C07D 413/04^(2006.01)

(86)	International application number:
	PCT/GB2014/052511

(87)	International publication number:
	WO 2015/022547 (19.02.2015 Gazette 2015/07)

(54)	BICYCLIC PLASMA KALLIKREIN INHIBITORS BICYCLISCHE PLASMA KALLIKREIN INHIBITOREN INHIBITEURS BICYCLIQUES DE PLASMA KALLIKREIN

(84)	Designated Contracting States:
	AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

(30)

Priority:

14.08.2013 GB 201314578
14.08.2013 US 201361865696 P

(43)	Date of publication of application:
	22.06.2016 Bulletin 2016/25

(73)	Proprietor: Kalvista Pharmaceuticals Limited
	Porton Down Wiltshire SP4 0BF (GB)

(72)	Inventors:
	EDWARDS, Hannah Joy Wiltshire SP4 0BF (GB) EVANS, David Michael Wiltshire SP4 0BF (GB) DAVIE, Rebecca Louise Wiltshire SP4 0BF (GB) ROOKER, David Philip Wiltshire SP4 0BF (GB) HEWISON, Steven John Hinckley Leicestershire LE10 1SW (GB)

(74)	Representative: Carpmaels & Ransford LLP
	One Southampton Row London WC1B 5HA London WC1B 5HA (GB)

(56)

References cited: :

WO-A1-2011/118672

WO-A1-2013/111108

Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).